RxDoctor Payments Data

Maya Rayzman, MD

Internal Medicine · Jamaica, NYNPI 1952356107

Payments from drug & device makers

$4,080in general payments, 2019–2025

Across 38 payments — averaging $107.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$823
  • Boehringer Ingelheim$699
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$615
  • Amgen$500
  • AstraZeneca$452
  • Novo Nordisk$334
  • plus $659 from 6 others

What the payments were for

  • Food & beverage$4,080100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,080 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$33,012
Medicare patients
85
Services billed
347

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin59$78,334
EliquisApixaban55$73,764
JanuviaSitagliptin Phosphate35$43,189
FarxigaDapagliflozin Propanediol13$16,250
Atorvastatin Calcium532$7,371
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$5,567
RestasisCyclosporine12$5,135
Novolog FlexpenInsulin Aspart15$5,053
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate25$4,937
Amlodipine Besylate645$4,657
Losartan Potassium254$3,678
Albuterol Sulfate HfaAlbuterol Sulfate97$3,529
Metoprolol Succinate160$3,103
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$2,903
Hydralazine Hcl145$2,083

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$699$78,33459 claims
MerckJanuvia$98$43,18935 claims
AstraZenecaFarxiga$452$16,25013 claims
AbbVieRestasis, Synthroid$823$6,78946 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Jamaica

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →